View Future GrowthCOFCO Biotechnology 과거 순이익 실적과거 기준 점검 0/6COFCO Biotechnology 의 수입은 연평균 -54.4%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 5.6%의 비율로 감소했습니다. 매출은 연평균 4.9%의 비율로 감소해 왔습니다.핵심 정보-54.36%순이익 성장률-54.38%주당순이익(EPS) 성장률Chemicals 산업 성장률12.10%매출 성장률-4.88%자기자본이익률-1.11%순이익률-0.73%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공시 • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025공시 • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공시 • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025모든 업데이트 보기Recent updates공시 • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Employee Supervisor Zhi Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Apr 24COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China공시 • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025공시 • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공시 • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China공시 • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.028 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥5.21b (down 3.7% from 3Q 2023). Net loss: CN¥51.9m (down CN¥54.3m from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024공시 • Sep 21COFCO Biotechnology Co., Ltd. Announces Board ChangesCOFCO Biotechnology Co., Ltd. at its EGM held on 19 September 2024 appointed Zhang Deguo, Zheng Heshan as non-independent director; appointed Zhang Nianchun and Wang Ping as independent director.Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.02 (up from CN¥0.18 loss in 2Q 2023). Revenue: CN¥5.18b (up 8.2% from 2Q 2023). Net income: CN¥36.6m (up CN¥373.3m from 2Q 2023). Profit margin: 0.7% (up from net loss in 2Q 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.공시 • Jun 29COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024COFCO Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024Board Change • Jun 12High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. GM & Non-Independent Director De Guo Zhang is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.013 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥4.73b (up 4.6% from 1Q 2023). Net income: CN¥24.8m (up CN¥23.4m from 1Q 2023). Profit margin: 0.5% (up from 0% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.공시 • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaitai Int'l Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China공시 • Mar 30COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024공시 • Dec 29COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 0.2% per year over the past 5 years.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.097 in 3Q 2022). Revenue: CN¥5.41b (up 26% from 3Q 2022). Net income: CN¥2.38m (down 99% from 3Q 2022). Profit margin: 0% (down from 4.2% in 3Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Buying Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.Buying Opportunity • Aug 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)Second quarter 2023 results: CN¥0.18 loss per share (down from CN¥0.23 profit in 2Q 2022). Revenue: CN¥4.79b (down 8.4% from 2Q 2022). Net loss: CN¥336.7m (down 177% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.공시 • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.공시 • May 20+ 1 more updateCOFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee SupervisorCOFCO Biotechnology Co., Ltd. at its Annual General Meeting of 2022 held on 18 May 2023, approved the election of Wang Laichun as a Non-Employee Supervisor.Reported Earnings • Apr 16Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.57 (down from CN¥0.61 in FY 2021). Revenue: CN¥19.9b (down 15% from FY 2021). Net income: CN¥1.06b (down 6.6% from FY 2021). Profit margin: 5.3% (up from 4.8% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.097 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥4.29b (down 29% from 3Q 2021). Net income: CN¥179.7m (down 24% from 3Q 2021). Profit margin: 4.2% (up from 3.9% in 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥5.23b (down 18% from 2Q 2021). Net income: CN¥436.7m (up 25% from 2Q 2021). Profit margin: 8.4% (up from 5.5% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 8.2%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥5.38b (down 4.3% from 1Q 2021). Net income: CN¥349.0m (down 1.9% from 1Q 2021). Profit margin: 6.5% (up from 6.3% in 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥6.06b (up 30% from 3Q 2020). Net income: CN¥234.9m (up 40% from 3Q 2020). Profit margin: 3.9% (up from 3.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Board Change • Sep 12High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Sep 09High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥6.38b (up 22% from 2Q 2020). Net income: CN¥350.2m (up 32% from 2Q 2020). Profit margin: 5.5% (up from 5.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 15Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥19.9b (up 2.2% from FY 2019). Net income: CN¥593.1m (flat on FY 2019). Profit margin: 3.0% (in line with FY 2019).Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥9.07, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 27.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past year are 11%.Is New 90 Day High Low • Jan 25New 90-day high: CN¥10.11The company is up 19% from its price of CN¥8.47 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 25% over the same period.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥9.64, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20.8x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past year are 43%.Is New 90 Day High Low • Jan 05New 90-day high: CN¥9.64The company is up 15% from its price of CN¥8.39 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period.Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥737.4m, up 120% from the prior year. Total revenue was CN¥19.6b over the last 12 months, up 6.2% from the prior year.매출 및 비용 세부 내역COFCO Biotechnology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XSEC:000930 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비31 Mar 2617,005-12475912331 Dec 2517,5123874916030 Sep 2518,1919581715530 Jun 2518,9557184914731 Mar 2519,7074187615231 Dec 2420,0532586212930 Sep 2420,782-25983015930 Jun 2420,980-20581117531 Mar 2420,588-57877717031 Dec 2320,379-60278916530 Sep 2319,743-24079714930 Jun 2318,619-6379811831 Mar 2319,06071179411901 Jan 2319,9181,05980713330 Sep 2220,3701,1607778530 Jun 2222,1421,21578011431 Mar 2223,3201,12382713201 Jan 2223,5601,13081511930 Sep 2124,01199483713530 Jun 2122,63092884014431 Mar 2121,46084879510531 Dec 2019,90959379911430 Sep 2019,5697371,02813130 Jun 2019,8837721,26310131 Mar 2018,9356361,5659131 Dec 1919,4725931,8108730 Sep 1918,4243321,7996530 Jun 1917,7203041,9218031 Mar 1917,8504301,8468231 Dec 1817,7044831,8519630 Sep 1824,4801,2542,78917630 Jun 1821,8481,0702,33616831 Mar 1818,8219672,05814631 Dec 1715,8929291,76810130 Sep 176,1642374602230 Jun 175,898339497031 Mar 175,854232555031 Dec 165,603127558030 Sep 165,446-801608030 Jun 165,593-1,083612031 Mar 166,186-1,265553031 Dec 156,457-1,418535030 Sep 156,704-509456030 Jun 157,155-3124750양질의 수익: 000930 은(는) 현재 수익성이 없습니다.이익 마진 증가: 000930는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 000930은 수익성이 없으며 지난 5년 동안 손실이 연평균 54.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 000930의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 000930은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(3.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 000930는 현재 수익성이 없으므로 자본 수익률이 음수(-1.11%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/13 01:52종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스COFCO Biotechnology Co., Ltd.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Xia ShengCitic Securities Co., Ltd.Wei LiuHaitong International Research LimitedJiao ChenIndustrial Securities Co. Ltd.1명의 분석가 더 보기
공시 • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025
공시 • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공시 • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
공시 • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.
Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Employee Supervisor Zhi Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Apr 24COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
공시 • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025
공시 • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공시 • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
공시 • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
공시 • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.028 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥5.21b (down 3.7% from 3Q 2023). Net loss: CN¥51.9m (down CN¥54.3m from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024
공시 • Sep 21COFCO Biotechnology Co., Ltd. Announces Board ChangesCOFCO Biotechnology Co., Ltd. at its EGM held on 19 September 2024 appointed Zhang Deguo, Zheng Heshan as non-independent director; appointed Zhang Nianchun and Wang Ping as independent director.
Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.02 (up from CN¥0.18 loss in 2Q 2023). Revenue: CN¥5.18b (up 8.2% from 2Q 2023). Net income: CN¥36.6m (up CN¥373.3m from 2Q 2023). Profit margin: 0.7% (up from net loss in 2Q 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
공시 • Jun 29COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024COFCO Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024
Board Change • Jun 12High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. GM & Non-Independent Director De Guo Zhang is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.013 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥4.73b (up 4.6% from 1Q 2023). Net income: CN¥24.8m (up CN¥23.4m from 1Q 2023). Profit margin: 0.5% (up from 0% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
공시 • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaitai Int'l Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
공시 • Mar 30COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
공시 • Dec 29COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024
New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 0.2% per year over the past 5 years.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.097 in 3Q 2022). Revenue: CN¥5.41b (up 26% from 3Q 2022). Net income: CN¥2.38m (down 99% from 3Q 2022). Profit margin: 0% (down from 4.2% in 3Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공시 • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Buying Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
Buying Opportunity • Aug 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)Second quarter 2023 results: CN¥0.18 loss per share (down from CN¥0.23 profit in 2Q 2022). Revenue: CN¥4.79b (down 8.4% from 2Q 2022). Net loss: CN¥336.7m (down 177% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.
공시 • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.
공시 • May 20+ 1 more updateCOFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee SupervisorCOFCO Biotechnology Co., Ltd. at its Annual General Meeting of 2022 held on 18 May 2023, approved the election of Wang Laichun as a Non-Employee Supervisor.
Reported Earnings • Apr 16Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.57 (down from CN¥0.61 in FY 2021). Revenue: CN¥19.9b (down 15% from FY 2021). Net income: CN¥1.06b (down 6.6% from FY 2021). Profit margin: 5.3% (up from 4.8% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.097 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥4.29b (down 29% from 3Q 2021). Net income: CN¥179.7m (down 24% from 3Q 2021). Profit margin: 4.2% (up from 3.9% in 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥5.23b (down 18% from 2Q 2021). Net income: CN¥436.7m (up 25% from 2Q 2021). Profit margin: 8.4% (up from 5.5% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 8.2%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥5.38b (down 4.3% from 1Q 2021). Net income: CN¥349.0m (down 1.9% from 1Q 2021). Profit margin: 6.5% (up from 6.3% in 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥6.06b (up 30% from 3Q 2020). Net income: CN¥234.9m (up 40% from 3Q 2020). Profit margin: 3.9% (up from 3.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Board Change • Sep 12High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Sep 09High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥6.38b (up 22% from 2Q 2020). Net income: CN¥350.2m (up 32% from 2Q 2020). Profit margin: 5.5% (up from 5.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 15Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥19.9b (up 2.2% from FY 2019). Net income: CN¥593.1m (flat on FY 2019). Profit margin: 3.0% (in line with FY 2019).
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥9.07, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 27.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past year are 11%.
Is New 90 Day High Low • Jan 25New 90-day high: CN¥10.11The company is up 19% from its price of CN¥8.47 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 25% over the same period.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥9.64, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20.8x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past year are 43%.
Is New 90 Day High Low • Jan 05New 90-day high: CN¥9.64The company is up 15% from its price of CN¥8.39 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period.
Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥737.4m, up 120% from the prior year. Total revenue was CN¥19.6b over the last 12 months, up 6.2% from the prior year.